Expression of biologically active human TRAIL in transgenic pigs

Transplantation

Volumn 80, Issue 2, 2005, Pages 222-230

  Klose, Regina ^a   Kemter, Elisabeth ^a   Bedke, Tanja ^b   Bittmann, Iris ^a   Keßler, Barbara ^a   Endres, Robert ^c   Pfeffer, Klaus ^d   Schwinzer, Reinhard ^b   Wolf, Eckhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Universität Düsseldorf ^*

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Transgenic pigs; Tumor necrosis factor related apoptosis inducing ligand (TRAIL); Xenotransplantation

Indexed keywords

ACTIN; CONCANAVALIN A; GENOMIC DNA; MONOCLONAL ANTIBODY; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; EMBRYO TRANSFER; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SOUTHERN BLOTTING; SWINE; TISSUE CULTURE; TRANSGENE; TRANSGENIC ANIMAL; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, SOUTHERN; CELL LINE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MELANOMA; MEMBRANE GLYCOPROTEINS; SWINE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044485933     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000164817.59006.C2     Document Type: Article

References (52)

1. Cooper DK, Keogh AM, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: The present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant 2000; 19: 1125-1165.
2. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-966.
3. Swindle MM, Smith AC, Lanber-Laird K, et al. Swine in biomedical research. ILAR News 1994; 36: 1-5.
4. Bach FH, Robson SC, Winkler H, et al. Barriers to xenotransplantation. Nat Med 1995; 1: 869-873.
5. Logan JS. Prospects for xenotransplantation. Curr Opin Immunol 2000; 12: 563-568.
6. Cozzi E, Bhatti F, Schmoeckel M, et al. Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation 2000; 70: 15-21.
7. Niemann H, Verhoeyen E, Wonigeit K, et al. Cytomegalovirus early promoter induced expression of hCD59 in porcine organs provides protection against hyperacute rejection. Transplantation 2001; 72: 1898-1906.
8. Denning C, Burl S, Ainslie A, et al. Deletion of the alpha(1,3)galactosyl transferase (GGTA1) gene and the prion protein (PrP) gene in sheep. Nat Biotechnol 2001; 19: 559-562.
9. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
10. Ramsoondar JJ, Machaty Z, Costa C, et al. Production of alpha 1,3-galactosyltransferase-knockout cloned pigs expressing human alpha 1,2-fucosylosyltransferase. Biol Reprod 2003; 69: 437-445.
11. Kuwaki K, Tsen Y-L, Dor FJMF, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: Initial experience. Nat Med 2005; 11: 29-31.
12. Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3- galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11: 32-34.
13. Dorling A, Lombardi G, Binns R, et al. Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. Eur J Immunol 1996; 26: 1378-1387.
14. Murray AG, Khodadoust MM, Pober JS, et al. Porcine aortic endothelial cells activate human T cells: Direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity 1994; 1: 57-63.
15. Yamada K, Sachs DH, DerSimonian H. Human anti-porcine xenogeneic T cell response: Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J Immunol 1995; 155: 5249-5256.
16. Friedman T, Shimizu A, Smith RN, et al. Human CD4+ T cells mediate rejection of porcine xenografts. J Immunol 1999; 162: 5256-5262.
17. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis family. Cell 1993; 75: 1169-1178.
18. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
19. Takeuchi T, Ueki T, Nishimatsu H, et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 1999; 162: 518-522.
20. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
21. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260.
22. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
23. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818.
24. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
25. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
26. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003-1006.
27. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-820.
28. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
29. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
30. Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-1361.
31. Liu S, Yu Y, Zhang M, et al. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 2001; 166: 5407-5415.
32. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94-100.
33. Ursini-Siegel J, Zhang W, Altmeyer A, et al. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol 2002; 169: 5505-5513.
34. Renshaw SA, Parmar JS, Singleton V, et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003; 170: 1027-1033.
35. Kamohara H, Matsuyama W, Shimozato O, et al. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology 2004; 111: 186-194.
36. Song K, Chen Y, Goke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191: 1095-1104.
37. Lunemann JD, Waiczies S, Ehrlich S, et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002; 168: 4881-4888.
38. Xie L, Shi W, Guo P. Roles of tumor necrosis factor-related apoptosis-inducing ligand in corneal transplantation. Transplantation 2003; 76: 1556-1559.
39. Plitz T, Huffstadt U, Endres R, et al. The resistance against Listeria monocytogenes and the formation of germinal centers depend on a functional death domain of the 55 kDa tumor necrosis factor receptor. Eur J Immunol 1999; 29: 581-591.
40. Besenfelder U, Modi J, Muller M, et al. Endoscopic embryo collection and embryo transfer into the oviduct and the uterus of pigs. Theriogenology 2002; 47: 1051-1060.
41. Dulat HJ, von Grumbkow C, Baars W, et al. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol 2001; 31: 2217-2226.
42. van Denderen BJ, Pearse MJ, Katerelos M, et al. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 1996; 61: 582-588.
43. Somerville CA, Kyriazis AG, McKenzie A, et al. Functional expression of human CD59 in transgenic mice. Transplantation 1994; 58: 1430-1435.
44. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153-11157.
45. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149-155.
46. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
47. David-Watine B, Israel A, Kourilsky P. The regulation and expression of MHC class I genes. Immunol Today 1990; 11: 286-292.
48. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28: 973-982.
49. Jeremias I, Herr I, Boehler T, et al. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998; 28: 143-152.
50. Marsters SA, Pitti RM, Donahue CJ, et al. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996; 6: 750-752.
51. Simon AK, Williams O, Mongkolsapaya J, et al. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes. Proc Natl Acad Sci USA 2001; 98: 5158-5163.
52. Hofmann A, Kessler B, Ewerling S, et al. Efficient transgenesis in farm animals by lentiviral vectors. EMBO Rep 2003; 4: 1054-1060.